<DOC>
	<DOCNO>NCT00030745</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Giving chemotherapy drug surgery may shrink tumor remove surgery . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat patient mesothelioma lung .</brief_summary>
	<brief_title>Combination Chemotherapy Before Surgery Treating Patients With Mesothelioma Lung</brief_title>
	<detailed_description>OBJECTIVES : - Determine proportion patient potentially resectable mesothelioma pleura remain operable treatment neoadjuvant cisplatin gemcitabine . - Determine response rate overall survival patient treat regimen . - Determine tolerability regimen patient . - Determine number postoperative hospitalization day occurrence duration surgical complication patient treat regimen . - Determine quality life patient treat regimen . - Compare proportion patient report psychological distress 3 month surgery v study registration . OUTLINE : Patients receive cisplatin IV day 1 gemcitabine IV day 1 , 8 , 15 . Treatment repeat every 28 day 3 course . Within 6 week completion chemotherapy , patient undergo restaging CT scan follow surgical resection . Quality life assess baseline , day 1 course 3 , within 4 week surgery , 3 6 month . Patients follow every 3 month 1 year every 6 month thereafter . PROJECTED ACCRUAL : A total 61 patient accrue study .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically clinically confirm pleural mesothelioma Stages T13 , N02 , M0 CT scan chest Mediastinoscopy require staging mediastinal lymph node Considered completely resectable PATIENT CHARACTERISTICS : Age : Over 18 Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : No severe liver disease Renal : Creatinine great 1.7 mg/dL Cardiac : Adequate cardiac function No cardiac disease would preclude forced hydration surgery Pulmonary : Predicted postoperative FEV_1 great 1 spirometry Other : No contraindication surgery No prior concurrent malignancy except adequately treat carcinoma situ cervix basal cell squamous cell skin cancer No uncontrolled infection No uncontrolled diabetes No neurologic psychiatric disorder would preclude study compliance No serious illness would preclude study participation No circumstance would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery No prior pleurectomy lung resection except diagnostic purpose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>stage IA malignant mesothelioma</keyword>
	<keyword>stage IB malignant mesothelioma</keyword>
	<keyword>stage II malignant mesothelioma</keyword>
	<keyword>stage III malignant mesothelioma</keyword>
</DOC>